Literature DB >> 24131687

Characteristics of antibody responses in West Nile virus-seropositive blood donors.

Paul J Carson1, Harry E Prince, Brad J Biggerstaff, Robert Lanciotti, Leslie H Tobler, Michael Busch.   

Abstract

West Nile virus (WNV) is now endemic in the United States. Protection against infection is thought to be conferred in part by humoral immunity. An understanding of the durability and specificity of the humoral response is not well established. We studied the magnitude and specificity of antibody responses in 370 WNV-seropositive blood donors. We also recalled 18 donors who were infected in 2005 to compare their antibody responses at 6 months following infection versus at 5 years postinfection. There were no significant differences in IgG antibody levels based on age, sex, or recent infection (as evidenced by IgM positivity). Specific antibody responses by viral plaque reduction neutralization testing (PRNT) were seen in 51/54 subjects evaluated. All donors who were seropositive in 2005 remained seropositive at 5 years and maintained neutralizing antibodies. IgG levels at 5 years postinfection showed fairly minimal decreases compared with the paired levels at 6 months postinfection (mean of paired differences,-0.54 signal-to-cutoff ratio (S/CO) units [95% confidence interval {CI}, -0.86 to -0.21 S/CO units]) and only minimal decreases in PRNT titers. WNV induces a significant antibody response that remains present even 5 years after infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24131687      PMCID: PMC3911469          DOI: 10.1128/JCM.01932-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

1.  Serum dilution neutralization test for California group virus identification and serology.

Authors:  H S Lindsey; C H Calisher; J H Mathews
Journal:  J Clin Microbiol       Date:  1976-12       Impact factor: 5.948

2.  Antibody to dengue 1 detected more than 60 years after infection.

Authors:  Allison Imrie; Janet Meeks; Alexandra Gurary; Munkhzul Sukhbaatar; Thang Thua Truong; C Bruce Cropp; Paul Effler
Journal:  Viral Immunol       Date:  2007-12       Impact factor: 2.257

3.  Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine.

Authors:  J D Poland; C H Calisher; T P Monath; W G Downs; K Murphy
Journal:  Bull World Health Organ       Date:  1981       Impact factor: 9.408

4.  Serological studies on volunteers inoculated experimentally with a dengue virus strain in 1943.

Authors:  Y Okuno; T Fukunaga; M Tadano; K Fukai; T Ikeda; K Sekii; H Ariyoshi
Journal:  Biken J       Date:  1983-12

5.  Performance of immunoglobulin G (IgG) and IgM enzyme-linked immunosorbent assays using a West Nile virus recombinant antigen (preM/E) for detection of West Nile virus- and other flavivirus-specific antibodies.

Authors:  Wayne R Hogrefe; Ronald Moore; Mary Lape-Nixon; Michael Wagner; Harry E Prince
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

6.  Neurologic manifestations and outcome of West Nile virus infection.

Authors:  James J Sejvar; Maryam B Haddad; Bruce C Tierney; Grant L Campbell; Anthony A Marfin; Jay A Van Gerpen; Aaron Fleischauer; A Arturo Leis; Dobrivoje S Stokic; Lyle R Petersen
Journal:  JAMA       Date:  2003-07-23       Impact factor: 56.272

Review 7.  The structural immunology of antibody protection against West Nile virus.

Authors:  Michael S Diamond; Theodore C Pierson; Daved H Fremont
Journal:  Immunol Rev       Date:  2008-10       Impact factor: 12.988

8.  Flavivirus serology by Western blot analysis.

Authors:  Leopoldo F Oceguera; Peter J Patiris; Robert E Chiles; Michael P Busch; Leslie H Tobler; Carl V Hanson
Journal:  Am J Trop Med Hyg       Date:  2007-07       Impact factor: 2.345

9.  Virus and antibody dynamics in acute west nile virus infection.

Authors:  Michael P Busch; Steven H Kleinman; Leslie H Tobler; Hany T Kamel; Philip J Norris; Irina Walsh; Jose L Matud; Harry E Prince; Robert S Lanciotti; David J Wright; Jeffrey M Linnen; Sally Caglioti
Journal:  J Infect Dis       Date:  2008-10-01       Impact factor: 5.226

Review 10.  Innate and adaptive immune responses determine protection against disseminated infection by West Nile encephalitis virus.

Authors:  Michael S Diamond; Bimmi Shrestha; Erin Mehlhop; Elizabeth Sitati; Michael Engle
Journal:  Viral Immunol       Date:  2003       Impact factor: 2.257

View more
  4 in total

1.  Neutralizing antibodies against West Nile virus identified directly from human B cells by single-cell analysis and next generation sequencing.

Authors:  Konstantinos Tsioris; Namita T Gupta; Adebola O Ogunniyi; Ross M Zimnisky; Feng Qian; Yi Yao; Xiaomei Wang; Joel N H Stern; Raj Chari; Adrian W Briggs; Christopher R Clouser; Francois Vigneault; George M Church; Melissa N Garcia; Kristy O Murray; Ruth R Montgomery; Steven H Kleinstein; J Christopher Love
Journal:  Integr Biol (Camb)       Date:  2015-10-20       Impact factor: 2.192

2.  West Nile virus nucleic acid persistence in whole blood months after clearance in plasma: implication for transfusion and transplantation safety.

Authors:  Marion C Lanteri; Tzong-Hae Lee; Li Wen; Zhanna Kaidarova; Marjorie D Bravo; Nancy E Kiely; Hany T Kamel; Leslie H Tobler; Philip J Norris; Michael P Busch
Journal:  Transfusion       Date:  2014-06-26       Impact factor: 3.157

3.  Of Mice and Men: Protective and Pathogenic Immune Responses to West Nile virus Infection.

Authors:  Derek Trobaugh; Sharone Green
Journal:  Curr Trop Med Rep       Date:  2015-03-01

Review 4.  Current developments in understanding of West Nile virus central nervous system disease.

Authors:  Kenneth L Tyler
Journal:  Curr Opin Neurol       Date:  2014-06       Impact factor: 5.710

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.